Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

0.8990 +0.0090 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Path Holdings

< Previous 1 2 3 4 5 6 7 Next >
Bio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid Leukemia
Bio-Path Holdings Inc (NASDAQ: BPTH) reported interim data from Stage 2 of the company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for  
Via Benzinga
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Bio-Path Holdings Earnings Preview
Via Benzinga
A Preview Of Bio-Path Holdings's Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Why Is FibroGen (FGEN) Stock Down 81% Today?
FibroGen (FGEN) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint. 
Via InvestorPlace
Why Is MoonLake Immunotherapeutics (MLTX) Stock Up 93% Today?
MoonLake Immunotherapeutics (MLTX) stock is taking off on Monday after reporting positive results from a Phase 2 clinical trial. 
Via InvestorPlace
Why Is Bio-Path (BPTH) Stock Down 12% Today?
Bio-Path (BPTH) stock is sliding lower on Monday after the biotechnology company announced a proposed public share offering. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23
Dallas, Texas--(Newsfile Corp. - June 2, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
Bio-Path Holdings Reports First Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22
Dallas, Texas--(Newsfile Corp. - April 10, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): The... 
Via Newsfile
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides Clinical and Operational Update
Company Expects to Achieve Several Near-Term Clinical Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22
Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path... 
Via Newsfile
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Q3 2022 Earnings Conference Call On November 15, 2022 At 08:30 AM ET
Bio-Path Holdings (NASDAQ:BPTH) will host a conference call at 08:30 AM ET on November 15, 2022, to discuss Q3 2022 earnings results. How to Attend Bio-Path Holdings (BPTH) Conference Call Follow this... 
Via Benzinga
Analyzing Bio-Path Holdings's Short Interest
Bio-Path Holdings's (NASDAQ:BPTH) short percent of float has fallen 10.42% since its last report. The company recently reported that it has 34 thousand shares sold short, which is 0.43% of all regular... 
Via Benzinga
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.